Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Nuvaira, Inc.
Age
40–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
FEV1 30% to 60%
Patient is diagnosed with COPD
Positive relative change in FEV1 of greater than 15%
Patient 40 years of age or older at the time of consent
Smoking history of at least 10 pack years
Non-smoking for a minimum of 6 months prior to consent and agrees to continue not smoking for the duration of the study
You may not be if
Documented history or current evidence of pulmonary hypertension Documented history or current evidence of polycythemia level of greater
Documented history or current evidence of congestive heart failure
Patient has an SaO2 less than or equal to 88% or a PaO2 less than or equal to 7.3 kPa (55 mm Hg) on room air
Patient has a PaCO2 \> 8.0 kPa (60 mm Hg)
Prior lung transplant, LVRS, LVR, median sternotomy, bullectomy or lobectomy
Pulmonary nodule requiring surgery
History of recurrent respiratory infections (more than 3 hospitalizations within 1 year of enrollment)
Presence of a pacemaker, internal defibrillator or other implantable electronic devices j. Active respiratory infection within the past 4 weeks k. COPD exacerbation within the past 4 weeks l. Myocardial infarction (MI) within the last 6 months m. Unstable or life threatening arrhythmia within the last year n. Malignancy treated with radiation or chemotherapy within the last 2 years o. Documented history of other respiratory diseases (cystic fibrosis, tuberculosis, vocal chord dysfunction, Churg-Strauss syndrome, allergic bronchopulmonary aspergillosis)
Clareo Health | Evaluation of the IPS System for TLD Therapy in Patients With COPD
